ALPACA Trial – Lepodisiran Significantly Reduces Lipoprotein(a) in Phase II Trial
Key Points Elevated lipoprotein(a) is associated with incident atherosclerotic cardiovascular disease and aortic stenosis The ALPACA trial randomized 320 patients... Read more.
TRILUMINATE– Transcatheter edge-to-edge repair reduces TR severity and HF Hospitalizations
Key Points The TRILUMINATE Pivotal trial previously reported that transcatheter edge-to-edge repair (TEER) improved quality-of-life compared to medical therapy alone... Read more.
PURSUIT Trial – Dose Dependent Reduction in LDL-C with AZD0780, Oral PCSK9 inhibitor
Key Points The majority of ASCVD patients fail to achieve guideline endorsed LDL targets The PURSUIT trial randomized 428 patients in a 1:1:1:1 ratio to receive... Read more.